Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve block before heart surgery may shield muscle from damage

NCT ID NCT06476925

Disease control Sponsor: Minia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a left stellate ganglion block, given before mitral valve replacement, could protect the heart muscle. 62 adults undergoing elective on-pump mitral valve replacement received either a saline placebo or bupivacaine nerve block. Researchers checked for microscopic heart muscle injury, arrhythmias, and troponin levels. The goal is to see if this simple procedure can reduce damage and improve recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bupivacaine
What this could lead to
If it works, this could lead to a simple procedure that reduces heart muscle damage and irregular heartbeats after mitral valve replacement.
What could go wrong
This is a small, single-center study with only 62 participants. The results may not apply to all heart surgery patients, and nerve blocks carry risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

62 people

The number who actually took part.

Started

Jul 2024

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult population of both sex, between 25-50 years, will undergo elective on pump mitral valve replacement Exclusion Criteria: * -Combined valve replacement ( mitral and aortic or mitral and tricuspid valves replacement). * Emergency valve replacement ( stuck valve, infective endocarditis). * Pre-operative cardiomyopathy (Ejection fraction less than 45%). * Recent myocardial infarction ( within 6 months) * Redo mitral valve replacement. * Pre-operative pacing, or cardioverter, any form arrhythmia ( tachy or brady). * Previous history of carotid endarterectomy or presence of carotid stent. * On thrombolytic therapy. * Severe chronic obstructive airway disease, * Patient refusal

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mitral valve disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mitral valve disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Open mitral cardiac surgery

Contacts and locations

Locations

  • Mina Raouf

    Minya, Minya Governorate, 61511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.